SpectraCure AB (2OK) AI Stock Analysis

0 Followers

SpectraCure AB

(Frankfurt:2OK)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low financial leverageLow debt reduces direct interest and refinancing pressure, giving SpectraCure more flexibility than a highly leveraged medtech company. This provides some capacity to pursue clinical development and commercialization without debt being the primary constraint on operations.

Negative Factors

No meaningful revenueThe absence of meaningful revenue alongside a large net loss shows that SpectraCure has not yet demonstrated commercial traction. Until sales begin to scale, the business lacks operating leverage and remains exposed to prolonged development and commercialization uncertainty.

SpectraCure AB (2OK) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap: EUR 1.93M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.1
Beta (1Y): -85.58
Revenue Growth: ―
EPS Growth: 15.38%
Country: Germany
Employees: 13
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

SpectraCure AB Business Overview & Revenue Model

Company Description

SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) sy...

SpectraCure AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2OK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:PAX	61Neutral	SEK 1.45B	-286.43	-1.22%	―	34.05%	-144.96%
SE:BACTI.B	53Neutral	SEK 539.68M	80.83	1.93%	―	-0.51%	―
SE:BRAIN	53Neutral	SEK 443.05M	-9.65	-22.23%	―	0.04%	34.45%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SDOS	40Underperform	SEK 31.36M	-3.56	―	―	-19.44%	-475.48%
SE:SCIB	30Underperform	SEK 158.85M	-0.67	-303.61%	―	51.21%	42.24%

* Healthcare Sector Average

Performance Comparison

DE:2OK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2OK	SpectraCure AB	―	―	―
SE:PAX	Paxman AB	62.50	1.90	3.14%
SE:SCIB	SciBase Holding AB	10.65	-9.24	-46.45%
SE:BACTI.B	Bactiguard Holding AB	14.55	-1.35	-8.49%
SE:BRAIN	BrainCool AB	1.12	0.59	109.33%
SE:SDOS	ScandiDos AB	0.44	-0.62	-58.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

SpectraCure AB AI Stock Analysis